Securities code: 600976 securities abbreviation: Jianmin Pharmaceutical Group Co.Ltd(600976) Announcement No.: 2022-01
Jianmin Pharmaceutical Group Co.Ltd(600976)
Announcement on the approval of qiruiweishu capsule for listing
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Recently, Jianmin Pharmaceutical Group Co.Ltd(600976) (hereinafter referred to as “the company”) learned from the website of the State Drug Administration that qiruiweishu capsule developed by the company was approved for listing. The relevant information is hereby announced as follows:
1、 Main contents of drugs approved for marketing
Drug name: qiruiweishu capsule
Dosage form: hard capsule
Specification: 0.5g per capsule
Registration classification: Traditional Chinese medicine class 1.1
Drug marketing license holder: Jianmin Pharmaceutical Group Co.Ltd(600976)
This product is an innovative traditional Chinese medicine developed on the basis of preparations in medical institutions. Randomized, double-blind, positive drug parallel control and multi center clinical trials have been carried out. The results of clinical trials show that it can be used for the treatment of epigastric pain caused by mild to moderate chronic non atrophic gastritis with erosion damp heat and blood stasis syndrome. The listing of this variety provides a new treatment option for patients with chronic gastritis.
2、 Drug R & D and related information
Drug name: qiruiweishu capsule
Indications: promoting blood circulation and removing blood stasis, drying dampness and relieving pain. It is used for epigastric pain caused by mild to moderate chronic non atrophic gastritis with erosion damp heat and blood stasis syndrome, purple and dark tongue or ecchymosis, yellow and greasy tongue coating, astringent pulse or smooth string.
Qiruiweishu capsule is composed of Panax notoginseng, dried alum, calcined pistil stone and other medicinal materials. The prescription comes from the hospital preparation of Guang’anmen Hospital of Chinese Academy of traditional Chinese medicine. It has a good foundation for clinical application, and its safety and effectiveness have been fully verified. At the same time, a series of pharmacological and toxicological studies and clinical trial research data of qiruiweishu capsule show that this product has significant curative effect in the treatment of chronic non atrophic gastritis with erosion, damp heat and blood stasis syndrome, especially in improving epigastric pain and traditional Chinese medicine syndrome, which is significantly better than the positive control drug, with good safety and good clinical application value.
Up to now, the cumulative R & D cost of qiruiweishu capsule is about 27.0482 million yuan.
3、 Market situation of similar drugs
According to epidemiological investigation, the incidence rate of digestive system in China is 30%. Because most of the patients with chronic gastritis do not have any symptoms, it is difficult to obtain the exact prevalence rate. In China, chronic gastritis accounts for 90% of the patients undergoing gastroscopy, and the rate of chronic non atrophic gastritis with erosion is 42.3% of chronic gastritis, and the incidence rate of chronic non atrophic gastritis is higher. According to the statistics of Intranet, stomach medicine (Chinese patent medicine) for gastritis and ulcer maintains a good market scale in the terminal of sample hospitals in China, including 7.380 billion yuan in 2019 and 6.747 billion yuan in 2020. At present, there are many varieties of stomach drugs used for gastritis and ulcer in China. According to the data of the terminal competition pattern of stomach drugs (Chinese patent medicine) used for gastritis and ulcer in China model hospitals on Intranet, there are 18 varieties with a market share of more than 1% in 2020, including Kangfuxin Liquid, Weisu granule, Qizhi Weitong granule, Yuanhu Zhitong dropping pill and Sanjiu Weitai granule, of which Kangfuxin Liquid accounts for 32.39% Weisu granule accounted for 11.3%, Qizhi Weitong granule for 4.65%, Yuanhu Zhitong dropping pill for 4.37%, Sanjiu Weitai granule for 3.45%. (the above data comes from “annual sales trend of [urban public, urban community, county-level public, township health] [Chinese patent medicine] [stomach medicine (gastritis, ulcer)] in China” and “top 20 pattern of product names of [urban public, urban community, county-level public, township health] [Chinese patent medicine] [stomach medicine (gastritis, ulcer)] in China”)
4、 Follow up arrangements for drug production and marketing
At present, the company has not received the relevant certificate of approval for the listing of qiruiweishu capsule issued by the State Drug Administration. Before Qirui Weishu Capsule goes on sale, the company will carry out a series of market development work and organize production and sales according to the requirements of national drug production quality management standards. The company strives to promote Qirui Weishu Capsule to be put into production and go on sale as soon as possible.
5、 Impact on listed companies and risk tips
Qiruiweishu capsule, an innovative traditional Chinese medicine developed by the company, has been approved for listing, which will further enrich the company’s product line in relevant treatment fields, help to enhance the company’s core competitiveness and have a positive impact on the company’s future development.
Although the market scale of stomach medicine (Chinese patent medicine) for gastritis and ulcer in China is large, and Qirui Weishu Capsule shows good therapeutic effect in clinical research, which can provide patients with new medication options, at present, some Chinese patent medicines for the treatment of chronic gastritis listed in China have a relatively stable market share, and drug sales are subject to pharmaceutical industry policies, bidding Under the influence of many factors such as changes in the market environment, there are uncertainties in the competition pattern, sales situation and whether the product can obtain a certain market share after listing.
The company’s product Qirui Weishu Capsule needs a series of production preparation and market development to achieve market sales. The Qirui Weishu Capsule is approved to be listed this time, which is not expected to have a great impact on the company’s performance in the short term.
Please invest rationally and pay attention to investment risks.
It is hereby announced.
Jianmin Pharmaceutical Group Co.Ltd(600976)
Board of directors
January 3, 2002
